What You Should Know:– Owkin, an AI-powered biotech company, today announced the dosing of the first patient in its Phase I clinical trial of OKN4395, a novel cancer therapy designed to restore immune function in patients with advanced solid tumors.– OKN4395 represents a novel approach to cancer treatment by targeting multiple immunosuppressive pathways simultaneously.OKN4395 BackgroundOKN4395 is a first-in-class asset that selectively inhibits three immunosuppressive receptors: EP2, EP4, and DP1. These receptors are known to play a role in tumor progression and resistance to immunotherapy. By blocking these pathways, OKN4395 aims to unleash the power of the immune system to fight cancer.The INVOKE Study (OKN-4395-121)The Phase Ia/1b clinical trial, known as INVOKE, is a global, multicenter, open-label study evaluating OKN4395 in patients with advanced solid tumors.Phase Ia: Assesses the safety and tolerability of OKN4395 as a monotherapy and in combination with pembrolizumab (an immunotherapy drug).Assesses the safety and tolerability of OKN4395 as a monotherapy and in combination with pembrolizumab (an immunotherapy drug). Phase Ib: Expands into four cohorts to evaluate preliminary anti-tumor activity, safety, and conduct extensive exploratory analyses.Owkin’s proprietary K1.0 Operating System played a crucial role in the development of OKN4395, from asset selection to clinical trial design. The AI platform was used to:Gain a deeper understanding of the target pathways: Analyze complex biological data to identify and validate the EP2/EP4/DP1 targets.Analyze complex biological data to identify and validate the EP2/EP4/DP1 targets. Optimize indication selection: Identify the most promising cancer types for OKN4395 treatment.Identify the most promising cancer types for OKN4395 treatment

Owkin, an end-to-end AI-biotech has announced Owkin K1.0 - a proprietary operating system (OS) for discovering new disease biology with the goal to become the first Artificial General Intelligence (AGI) for biology.

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients. “At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.” Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids